Newsroom

Stay up to date with what’s happening at ONO PHARMA USA.

Doctor meeting with a patient
Ono Pharmaceutical Co., Ltd. Announced 2022 Full Year Financial Results
Company
May 10, 2023
ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabs
Company
April 18, 2023
ONO PHARMA USA’s Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Central Nervous System Lymphoma
R & D
March 22, 2023
Ono Pharmaceutical Co., Ltd. Enters into a Collaboration and Option Agreement with Cue Biopharma for CUE-401, a Bispecific Protein
Licensing
February 24, 2023
Ono Pharmaceutical Co., Ltd. Supports for Relief Efforts in the Earthquake in Turkey and Syria
Company
February 17, 2023
Ono Pharmaceutical Co., Ltd. Announced 2022 3Q Financial Results
Company
January 31, 2023
Ono Pharmaceutical Co., Ltd. Acquires Multiple Research-Stage Oncology Programs from KSQ Therapeutics
Licensing
January 25, 2023
Ono Pharmaceutical Co., Ltd. Selected as a Highest Rating A-List Company for Both “Climate Change” and “Water Security” in CDP 2022
Sustainability
December 27, 2022
Ono Pharmaceutical Co., Ltd. Selected for the DJSI World Index and DJSI Asia Pacific Index for Three Straight Years
Sustainability
December 27, 2022
Ono Pharmaceutical Co., Ltd. and Equillium Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
Licensing
December 6, 2022